WHO Sounds Concern Over Critical Lack of Weight-Loss Jabs

Under one in 10 patients eligible to benefit from GLP-1 drugs such as Wegovy can access them, caution the World Health Organization as it issues its inaugural guidance on the therapies.

With in excess of 1,000,000,000 people worldwide now obese, it is calling for more widespread and fairer availability to this class of drugs.

Per projections, over two billion could be living with obesity by 2030 unless action is taken.

"The new guidance recognises that excess weight is a long-term condition that can be treated with comprehensive and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and distribution challenges are major barriers to broad availability to the jabs that can aid individuals in losing substantial body mass, notes the body.

Skinny Jab Supply Crisis

Even in the current most favorable case, the supply of GLP-1 therapies would only suffice for about 100 million people – less than 10% of those who need them, as stated by the health organization.

The advice encourages nations and manufacturers to increase access, via approaches such as voluntary licensing.

Exclusive production rights on a key compound – the main ingredient of a leading brand – is set to lapse in a number of nations in 2026.

How Weight-Loss Jabs Work

The injections mimick a biological compound to delay gastric emptying, reduce hunger and enhance feelings of fullness so users reduce food intake.

People commonly start to lose weight within a few weeks of beginning the weekly injections.

Evidence indicates patients may regain a significant portion a year later of halting the medication, as their typical hunger return.

Being above a healthy weight elevates your risk for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.

Obesity affects people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, per the WHO.